Drugs / Ulodesine
Ulodesine
also known as
BCX4208 · BCX-3408 · BCX-4208 HEMISUCCINATE HYDRATE · Dadme-immucillin h · LR-09 · R-3421 · Ulodesina · ULODESINE SUCCINATE
Small molecule targets PNP via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01407874 | Sep 2011 → Jul 2012 | arthritic joint disease, gout, impaired renal function disease | BioCryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01265264 | Dec 2010 → Jul 2012 | arthritic joint disease, gout | BioCryst Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01129648 | May → Nov 2010 | gout | BioCryst Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT00985127 | Sep 2009 → Sep 2010 | gout | BioCryst Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Reports Second Quarter 2010 Financial Results and Provides Corporate Update biocryst.com ↗
BioCryst today announces positive top-line results from its Phase 2a monotherapy BCX4208 gout study after completion of dose cohorts at 160 mg and 240 mg per day |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined with Allopurinol in Patients with Gout biocryst.com ↗
A dose-response was demonstrated for both BCX4208 and allopurinol, and the combination of BCX4208 and allopurinol was shown to be superior to either drug alone in sUA reduction. |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Reports Positive Results from Part One of Its Phase 2a Study of BCX4208 in Patients with Gout biocryst.com ↗
All three doses of BCX4208 demonstrated a statistically significant reduction in serum uric acid levels compared to placebo at day 22. |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Presents Results from Its BCX4208 Gout Program at the Annual European Congress of Rheumatology biocryst.com ↗
BCX4208 was safe and generally well-tolerated when added to allopurinol. |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology biocryst.com ↗
BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX) today presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, U.K. |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst to Present New Data for BCX4208 Monotherapy at the 74th Annual American College of Rheumatology (ACR) Scientific Meeting biocryst.com ↗
This poster concludes that BCX4208 doses administered at 40, 80, 120, 160 and 240 mg once-daily monotherapy rapidly and significantly reduced serum uric acid (sUA) in patients with gout. |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst to Present New BCX4208 Gout Results at the Annual European Congress of Rheumatology biocryst.com ↗
BCX4208 Shows Synergistic Reductions in Serum Uric Acid (sUA) in Gout Patients when Combined with Allopurinol |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Pharmaceuticals Presents New BCX4208 Gout Data at the 2011 ACR/ARHP Annual Scientific Meeting biocryst.com ↗
When added to allopurinol 300 mg, BCX4208 was superior to allopurinol plus placebo (p=0.009 overall). |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to Allopurinol Alone biocryst.com ↗
When added to allopurinol 300 mg, BCX4208 was superior to allopurinol plus placebo (p=0.009 overall). |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Announces Positive Results from Two Ulodesine Phase 2 Trials in Patients with Gout biocryst.com ↗
The results of the 52-week, blinded Phase 2b safety extension trial confirm that ulodesine continues to be generally safe and well-tolerated in gout patients who inadequately responded to allopurinol alone, many of which had multiple co-morbidities. |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout biocryst.com ↗
The results of this 24-week, blinded safety extension confirm that BCX4208 was generally safe and well-tolerated, and sustained sUA control over time. |
All press releases naming this drug 15 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ulodesine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01407874 ↗ |
| Known as | BCX-3408 | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | BCX-4208 HEMISUCCINATE HYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | BCX4208 | “Ulodesine (BCX4208) 5 mg” NCT01407874 ↗ |
| Known as | Dadme-immucillin h | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | LR-09 | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | R-3421 | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | Ulodesina | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | ULODESINE SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Action | Inhibit | “Purine nucleoside phosphorylase inhibitor” CHEMBL269864 ↗ |
| Modality | Small molecule | — CHEMBL269864 ↗ |
| Route | Oral | “Oral dose administered daily for 84 days.” NCT01265264 ↗ |
| Target | PNP | “Purine nucleoside phosphorylase inhibitor” CHEMBL269864 ↗ |